Abstracts tagged "giant cell arteritis"

Abstract Number: 2151 • 2016 ACR/ARHP Annual Meeting
Fractalkine (CX3CL1) Is Expressed By Arterial Endothelium and Vascular Smooth Muscle Cells (VSMC) in GCA
Marc Corbera-Bellalta¹, Ester Planas-Rigol², Nekane Terrades-Garcia¹, Marco Antonio Alba¹, Georgina Espígol-Frigolé², Sergio Prieto-González², Jose Hernández-Rodríguez¹ and Maria C. Cid³, ¹Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: The development of giant-cell arteritis (GCA) lesions requires amplification cascades resulting in continuous recruitment of lymphocytes and monocytes. Interferon-gamma (IFNg)- induced or up-regulated chemokines…
Abstract Number: 866 • 2016 ACR/ARHP Annual Meeting
Perivascular Inflammation in Temporal Artery Biopsies That Are Negative for Arteritis: Incidental or Harbinger?
Yousef Zarbalian¹, Kimberly P. Liang², Ronald L. Hamilton³, Li Wang⁴ and Dan Winger⁵, ¹Medicine, Division of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Pathology, Division of Neuropathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Office of Clinical Research, University of Pittsburgh, Pittsburgh, PA, ⁵Office of Clinical Research, Health Sciences, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The diagnosis of giant cell arteritis (GCA) by temporal artery (TA) biopsy requires pathologic identification of arterial inflammation, usually with giant cells. However, some…
Abstract Number: 2939 • 2016 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Matthew J. Koster² and Kenneth J. Warrington³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-analysis Background/Purpose: Venous thromboembolism (VTE) is a common medical problem with a…
Abstract Number: 867 • 2016 ACR/ARHP Annual Meeting
Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger⁴, Diana Dan⁴, Michael Seitz⁴ and Peter M. Villiger⁴, ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland, ⁴Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose:
Abstract Number: 3044 • 2016 ACR/ARHP Annual Meeting
Endothelin 1 Induces a Myofibroblastic Phenotype in Vascular Smooth Muscle Cells. A Mechanism Potentially Contributing to Vascular Remodeling and Intimal Hyperplasia in Giant Cell Arteritis
Ester Planas-Rigol¹, Nekane Terrades-Garcia², Marc Corbera-Bellalta², Ester Lozano², Marco Antonio Alba², Georgina Espígol-Frigolé³, Sergio Prieto-González², Marta Segarra², Jose Hernández-Rodríguez², Sara Preciado⁴, Rodolfo Lavilla⁴ and Maria C. Cid², ¹Vasculitis research unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Vasculitis Research Unit, Systemic Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴Laboratory of Organic Chemistry, Faculty of Pharmacy. Barcelona Science Park, Barcelona, Spain
Background/Purpose: Giant cell arteritis (GCA) is a vascular inflammatory disease involving large and medium sized arteries, particularly the cranial vessels. Inflammation-induced vascular remodeling leads to…
Abstract Number: 873 • 2016 ACR/ARHP Annual Meeting
Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis
Richard Conway¹, Karen Creevey², Michelle Trenkmann³, Geraldine M. McCarthy⁴, Conor Murphy⁵, Douglas J. Veale⁶, Ursula Fearon⁷ and Eamonn S. Molloy⁸, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²St. Vincent's University Hospital, Centre for Athritis and Rheuamtic Diseases, Dublin Academic Medical Centre,, Dublin, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁴Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁵Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁶Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁷Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁸Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis. The pathogenesis of GCA remains incompletely understood. Current evidence suggests that dendritic…
Abstract Number: 3182 • 2016 ACR/ARHP Annual Meeting
Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity
Berit Dalsgaard Nielsen¹, Ib Tønder Hansen², Kresten Krarup Keller³, Philip Therkildsen⁴, Ellen-Margrethe Hauge³ and Lars Christian Gormsen⁵, ¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, ⁵Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark
Background/Purpose: Fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT is, due to its excellent diagnostic accuracy[1], increasingly used to diagnose large vessel GCA (LV-GCA). However, PET/CT is not always readily…
Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Kimberly P. Liang¹, Douglas P. Landsittel², Bernadette B. Sendon³, Donald M. Jones⁴, Suresh R. Mulukutla⁵, Steven E. Reis⁶, Ali Hakim Shoushtari⁷ and Larry W. Moreland⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁷Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…
Abstract Number: 3183 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial
Stephan Reichenbach^1,2, Sabine Adler³, Jennifer Cullmann⁴, Harald Bonel⁴, Stefan Kuchen⁵, Felix Wermelinger¹, Diana Dan¹, Michael Seitz¹ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ⁴Department of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) of tocilizumab (TCZ) in giant cell arteritis (GCA) showed…
Abstract Number: 884 • 2016 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine Sreih², Gunnar Tomasson³, David Cuthbertson⁴, Simon Carette⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux¹³, Philip Seo¹⁴, Kenneth J. Warrington¹⁵, Steven R. Ytterberg¹⁶ and Peter A. Merkel¹⁷, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁴Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁵Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁶Rheumatology, Mayo Clinic, Rochester, MN, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: To evaluate health-related quality of life (HRQoL) in a large cohort of patients with giant cell arteritis (GCA) as measured by the 36-item…
Abstract Number: 3197 • 2016 ACR/ARHP Annual Meeting
Ultrasound Definitions for Cranial and Large Vessel Giant Cell Arteritis: Results of a Reliability Exercise on Images and Videos of the Omeract Ultrasound Large Vessel Vasculitis Task Force
Stavros Chrysidis¹, Christina Duftner², Christian Dejaco³, Cristina Ponte⁴, Annamaria Iagnocco⁵, Bhaskar Dasgupta⁶, Maria Antonietta D'Agostino⁷, Eugenio De Miguel⁸, Ulrich Fredberg⁹, Wolfgang Hartung¹⁰, Alojzija Hocevar¹¹, Tanaz A. Kermani¹², Matthew J. Koster¹³, Tove Lorenzen¹⁴, Pierluigi Macchioni¹⁵, Marcin Milchert¹⁶, Naina Rastalsky¹⁷, Chetan Mukhtyar¹⁸, Valentin S. Schaefer¹⁹, Kenneth J. Warrington²⁰, Lene Terslev²¹, George A. W. Bruyn²², Petra Hanova²³, Uffe Møller Døhn²⁴, Esperanza Naredo²⁵, Carlo Alberto Scirè²⁶, Greta Carrara²⁷, Sofia Ramiro²⁸, Andreas P Diamantopoulos²⁹ and Wolfgang A. Schmidt¹⁹, ¹Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ²Medical University Innsbruck, Innsbruck, Austria, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Rheumatology and Metabolic Bone Diseases Department, Rheumatology Research Unit - IMM, Lisbon Academic Medical Centre, Lisbon, Portugal, ⁵Sapienza Università Di Roma,, Roma, Italy, ⁶Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁸Hospital Universitario La Paz, Madrid, Spain, ⁹Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, ¹⁰Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹²Rheumatology, University of California Los Angeles, Santa Monica, CA, ¹³Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ¹⁴Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ¹⁵Arcispedale Santa Maria Nuova, Reggio Emilia,, Reggio Emilia, Italy, ¹⁶Pomeranian Medical University, Szczecin,, Szczecin, Poland, ¹⁷St. Elizabeth's Medical Center, Boston, MA, Boston, MA, ¹⁸Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹⁹Immanuel Krankenhaus Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, Germany, ²⁰Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²²Rheumatology, MC Groep, Loenga, Netherlands, ²³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ²⁵Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain, ²⁶Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ²⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ²⁸Leiden University Medical Center, Leiden, Netherlands, ²⁹Rheumatology, Haugesund Sanitetsforenings Revmatismesykehus, Haugesund, Norway
Background/Purpose: By a Delphi process, the OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal temporal arteries…
Abstract Number: 894 • 2016 ACR/ARHP Annual Meeting
Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?
Alexis Jones¹, Joe Li² and Charles Li³, ¹Rheumatology, University College London, LONDON, United Kingdom, ²Rheumatology, Royal Surrey County Hospital, Guildford, United Kingdom, ³Royal Surrey County Hospital, Guildford, Great Britain
Background/Purpose: The initial suspicion of Giant cell arteritis (GCA) is often made in the setting of primary care or casualty by a non-rheumatologist. Whilst temporal…
Abstract Number: 897 • 2016 ACR/ARHP Annual Meeting
Discordance Rates of Bilateral Temporal Artery Biopsies: A Retrospective Analysis
Jon Golenbiewski¹ and Alexandra Halalau², ¹Internal Medicine, Beaumont Health System, Oakland University William Beaumont School of Medicine, Royal Oak, MI, ²Beaumont Health System, Oakland University William Beaumont School of Medicine, Royal Oak, MI
Background/Purpose: Previous retrospective studies have suggested that simultaneous bilateral temporal artery biopsy (TAB) may lead to increased detection rates of giant cell arteritis (GCA). The term…
Abstract Number: 898 • 2016 ACR/ARHP Annual Meeting
Treatment and Outcome of Patients with a Diagnosis of Healed Arteritis on Temporal Artery Biopsy
Daniel Jo¹, Melissa Fazzari², Donald Brand³, Steven E. Carsons⁴ and Elise Belilos¹, ¹Rheumatology, Winthrop University Hospital, Mineola, NY, ²Biostatistics, Winthrop University Hospital, Mineola, NY, ³Office of Health Outcomes Research, Winthrop University Hospital, Mineola, NY, ⁴Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY
Background/Purpose: Temporal artery biopsy (TAB) is the gold standard for the diagnosis of Giant Cell Arteritis (GCA), yet is limited by the presence of skip…
Abstract Number: 1L • 2015 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – a Randomized Placebo-Controlled Trial
Sabine Adler¹, Stephan Reichenbach², Stefan Kuchen³, Felix Wermelinger², Diana Dan², Peter M. Villiger² and Michael Seitz², ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland
Background/Purpose: Giant cell arteritis (GCA) is characterized by a destructive, granulomatous inflammation in the walls of medium and large-sized arteries. Glucocorticoid (GC) treatment controls symptoms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].